Olanzapine treatment of residual positive and negative symptoms

被引:33
作者
Buchanan, RW [1 ]
Ball, MP [1 ]
Weiner, E [1 ]
Kirkpatrick, B [1 ]
Gold, JM [1 ]
McMahon, RP [1 ]
Carpenter, WT [1 ]
机构
[1] Univ Maryland, Dept Psychiat, Maryland Psychiat Res Ctr, Catonsville, MD 21228 USA
关键词
D O I
10.1176/appi.ajp.162.1.124
中图分类号
R749 [精神病学];
学科分类号
100205 [精神病与精神卫生学];
摘要
Objective: Olanzapine has been hypothesized to have superior efficacy in patients with treatment-resistant schizophrenia. The authors examined the comparative efficacy and safety of olanzapine and haloperidol in outpatients with partially responsive schizophrenia. Method: Sixty-three outpatients with schizophrenia who met retrospective and prospective criteria for either residual positive or residual negative symptoms entered a 16-week double-blind, parallel-groups comparison of olanzapine and haloperidol. Results: There were no significant differences between the two drugs in their effect on positive or negative symptoms. There were no significant differences between the two treatment groups on measures of social and functional outcome. Olanzapine-treated patients had a significant reduction in extrapyramidal symptoms and subjective measures of stiffness and dry mouth, but the increases in systolic blood pressure and weight in olanzapine-treated patients were significantly greater than they were in haloperidol-treated patients. Conclusions: Olanzapine has limited differential benefit for either positive or negative symptoms in patients with treatment-resistant schizophrenia. Although olanzapine is associated with fewer extrapyramidal symptoms, other side effects may offset this benefit.
引用
收藏
页码:124 / 129
页数:6
相关论文
共 27 条
[1]
Allison DB, 1999, AM J PSYCHIAT, V156, P1686
[2]
ANDREASEN NC, 1982, ARCH GEN PSYCHIAT, V39, P784
[3]
EFFECT OF ANTIPSYCHOTIC WITHDRAWAL ON EXTRAPYRAMIDAL SYMPTOMS - STATISTICAL-METHODS FOR ANALYZING SINGLE-SAMPLE REPEATED-MEASURES DATA [J].
ARNDT, S ;
DAVIS, CS ;
MILLER, DD ;
ANDREASEN, NC .
NEUROPSYCHOPHARMACOLOGY, 1993, 8 (01) :67-75
[4]
Charting patients' course: a comparison of statistics used to summarize patient course in longitudinal and repeated measures studies [J].
Arndt, S ;
Turvey, C ;
Coryell, WH ;
Dawson, JD ;
Leon, AC ;
Akiskal, HS .
JOURNAL OF PSYCHIATRIC RESEARCH, 2000, 34 (02) :105-113
[5]
Comparative efficacy of olanzapine and haloperidol for patients with treatment-resistant schizophrenia [J].
Breier, A ;
Hamilton, SH .
BIOLOGICAL PSYCHIATRY, 1999, 45 (04) :403-411
[6]
Buchanan RW, 1998, AM J PSYCHIAT, V155, P751
[7]
Clozapine: Efficacy and safety [J].
Buchanan, RW .
SCHIZOPHRENIA BULLETIN, 1995, 21 (04) :579-591
[8]
The Maryland Psychiatric Research Center scale and the characterization of involuntary movements [J].
Cassady, SL ;
Thaker, GK ;
Summerfelt, A ;
Tamminga, CA .
PSYCHIATRY RESEARCH, 1997, 70 (01) :21-37
[9]
Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia [J].
Conley, RR ;
Tamminga, CA ;
Bartko, JJ ;
Richardson, C ;
Peszke, M ;
Lingle, J ;
Hegerty, J ;
Love, R ;
Gounaris, C ;
Zaremba, S .
AMERICAN JOURNAL OF PSYCHIATRY, 1998, 155 (07) :914-920
[10]
Treatment-resistant schizophrenic patients respond to clozapine after olanzapine non-response [J].
Conley, RR ;
Tamminga, CA ;
Kelly, DL ;
Richardson, CM .
BIOLOGICAL PSYCHIATRY, 1999, 46 (01) :73-77